Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
© Lewis-Wambi et al.; licensee BioMed Central Ltd. 2008
Received: 04 September 2008
Accepted: 05 December 2008
Published: 05 December 2008
Estrogen deprivation using aromatase inhibitors is one of the standard treatments for postmenopausal women with estrogen receptor (ER)-positive breast cancer. However, one of the consequences of prolonged estrogen suppression is acquired drug resistance. Our group is interested in studying antihormone resistance and has previously reported the development of an estrogen deprived human breast cancer cell line, MCF-7:5C, which undergoes apoptosis in the presence of estradiol. In contrast, another estrogen deprived cell line, MCF-7:2A, appears to have elevated levels of glutathione (GSH) and is resistant to estradiol-induced apoptosis. In the present study, we evaluated whether buthionine sulfoximine (BSO), a potent inhibitor of glutathione (GSH) synthesis, is capable of sensitizing antihormone resistant MCF-7:2A cells to estradiol-induced apoptosis.
Estrogen deprived MCF-7:2A cells were treated with 1 nM 17β-estradiol (E2), 100 μM BSO, or 1 nM E2 + 100 μM BSO combination in vitro, and the effects of these agents on cell growth and apoptosis were evaluated by DNA quantitation assay and annexin V and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) staining. The in vitro results of the MCF-7:2A cell line were further confirmed in vivo in a mouse xenograft model.
Exposure of MCF-7:2A cells to 1 nM E2 plus 100 μM BSO combination for 48 to 96 h produced a sevenfold increase in apoptosis whereas the individual treatments had no significant effect on growth. Induction of apoptosis by the combination treatment of E2 plus BSO was evidenced by changes in Bcl-2 and Bax expression. The combination treatment also markedly increased phosphorylated c-Jun N-terminal kinase (JNK) levels in MCF-7:2A cells and blockade of the JNK pathway attenuated the apoptotic effect of E2 plus BSO. Our in vitro findings corroborated in vivo data from a mouse xenograft model in which daily administration of BSO either as a single agent or in combination with E2 significantly reduced tumor growth of MCF-7:2A cells.
Our data indicates that GSH participates in retarding apoptosis in antihormone-resistant human breast cancer cells and that depletion of this molecule by BSO may be critical in predisposing resistant cells to E2-induced apoptotic cell death. We suggest that these data may form the basis of improving therapeutic strategies for the treatment of antihormone resistant ER-positive breast cancer.
Currently, estrogen deprivation using aromatase inhibitors is one of the standard treatments for postmenopausal women with estrogen receptor (ER)-positive breast cancer . Unfortunately, a major clinical problem with the use of prolonged estrogen deprivation is the development of drug resistance (that is, hormone-independent growth) [2, 3]. Our laboratory as well as other investigators, have instigated a major effort in studying antihormone resistance in breast cancer and have developed model systems of estrogen deprivation that are sensitive [4–6] or resistant to the apoptotic actions of estrogen . In particular, we have previously reported the development of an estrogen deprived breast cancer cell line, MCF-7:5C, which undergoes estradiol-induced apoptosis after 2 days of treatment via the mitochondrial pathway . In contrast, we have another estrogen deprived breast cancer cell line, MCF-7:2A, which appears to be resistant to estradiol-induced apoptosis . We are studying resistance to estrogen induced apoptosis because clinical experience shows us that only 30% of patients respond to estrogen induced apoptosis once exhaustive antihormonal therapy occurs . An important goal would be to see whether the apoptotic effect of estrogen can be enhanced in antihormone resistant cells. This new, targeted approach to the treatment of metastatic breast cancer could open the door to novel approaches to treatment with drug combinations.
L-Buthionine sulfoximine (BSO) is a specific γ-glutamylcysteine synthetase inhibitor that blocks the rate-limiting step of glutathionine (GSH) biosynthesis and in doing so depletes the intracellular GSH pool in both cultured cells and in whole animals . GSH is a water-soluble tripeptide composed of glutamine, cysteine, and glycine. Reduced glutathione is the most abundant intracellular small molecule thiol present in mammalian cells and it serves as a potent intracellular antioxidant protecting cells from toxins such free radicals [11, 12]. Changes in GSH homeostasis have been implicated in the etiology and progression of a variety of human diseases, including breast cancer . In particular, studies have shown that elevated levels of GSH prevent apoptotic cell death whereas depletion of GSH facilitates apoptosis [10, 14]. BSO depletes cellular GSH  and sensitizes tumor cells to apoptosis induced by standard chemotherapeutic agents [15, 16].
Apoptosis (programmed cell death) is required for normal development and tissue homeostasis in multicellular organisms. Deregulation of apoptosis is fundamental to many diseases, such as cancer, stroke, heart disease, neurodegenerative disorders, and autoimmune disorders . There are two main pathways for apoptosis, namely the extrinsic receptor mediated pathway and the intrinsic mitochondria-mediated pathway [18, 19]. Components of the extrinsic pathway include the death receptors FasR/FasL, DR4/DR5, and tumor necrosis factor (TNF) , whereas the intrinsic pathway centers on the Bcl-2 family of proteins which comprises both proapoptotic proteins, such as Bax, Bak, and Bid and antiapoptotic proteins, such as Bcl-2 and Bcl-xL [18, 19]. The Bcl-2 family proteins regulate apoptosis by altering mitochondrial membrane permeabilization which leads to the release of apoptogenic factors such as cytochrome c, procaspases, and apoptosis inducing factor (AIF). In particular, Bcl-2 and Bcl-xL inhibit apoptosis by maintaining mitochondrial membrane integrity whereas Bax and Bak facilitate apoptosis by initiating the loss of outer mitochondrial integrity . Apart from its action on the mitochondria, there is also evidence that Bcl-2 possesses antioxidant property. Bcl-2 overexpression increases cellular GSH level which is associated with increased resistance to chemotherapy-induced apoptosis [22, 23] whereas GSH depletion restores apoptosis in Bcl-2 expressing cells .
Based on microarray studies we found that the antihormone resistant MCF-7:2A cells express markedly elevated levels of glutathione synthetase (GS) and glutathione peroxidase 2 (GPx2); two enzymes that are involved in glutathione synthesis, which suggests that resistance to estrogen-induced apoptosis might be due to elevated levels of GSH present in the cells. If MCF-7:2A cells do indeed possess high levels of GSH, then it is possible that the use of BSO – as a single agent – might be able to sensitize these cells to estrogen-induced apoptosis. As mentioned before, there is current clinical interest in using low dose estradiol therapy to treat antihormone resistant breast cancer  however only a minimal 30% of patients respond to this therapeutic strategy. A combination of BSO and estradiol could possibly be used to improve the efficacy of estradiol as an apoptotic agent if glutathione depletion is fundamental to tumor cell survival. We have addressed the hypothesis that by altering glutathione levels we may be able to enhance apoptosis to estrogen and have employed BSO as our agent of choice because of earlier work clinically, which may provide a foundation for subsequent clinical trials.
In the present study, we show that depletion of cellular GSH by BSO sensitizes antihormone-resistant MCF-7:2A cells to estradiol-induced apoptosis that is mediated, in part, by the mitochondrial pathway and also activation of the c-Jun N-terminal kinase (JNK) signaling pathway. We further show that BSO, either alone or in combination with estradiol, causes tumor regression of MCF-7:2A cells in vivo.
Materials and methods
Cell lines and reagents
The MCF-7 human breast cancer cell line was obtained from Dr Dean Edwards (University of Texas, San Antonio, TX, USA) and was maintained in phenol red RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 1 × non-essential amino acids and bovine insulin at 6 ng/mL. The clonal cell line, MCF-7:2A, was derived by growing MCF-7 cells in estrogen-free media for more than 1 year, followed by two rounds of limiting dilution cloning . These cells were grown in phenol red-free RPMI 1640 medium supplemented with 10% 4 × dextran-coated, charcoal-treated FBS (SFS). All reagents for cell culture were obtained from Invitrogen (Life Technologies, Carlsbad, CA, USA). DL-Buthionine sulfoximine (BSO) and 17β-estradiol (E2) were from Sigma (St Louis, MO, USA), rhodamine 123 (Rh123) was from Invitrogen (Life Technoligies, Carlsbad, CA, USA). LY294002 and SP600125 were from EMD (Gibbstown, NJ, USA)
Western blot analysis
The antibodies used for western blotting included those against stress-activated protein kinase (SAPK)/JNK, phospho-SAPK/JNK (Thr183/Tyr185), caspase-7, caspase-9, phospho-Bcl-2 (Ser70), and poly(ADP-ribose) polymerase (PARP) (Cell Signaling Technology, Danvers, MA, USA), cytochrome c and β-actin (Sigma, St Louis, MO, USA), cytochrome oxidase subunit IV (Cox IV; Invitrogen, Carlsbad, CA, USA), Bax, Bcl-2, and Bcl-xL (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Western blotting analysis was performed as previously described .
Cell proliferation assays
Proliferation assay was performed as previously described . Briefly, MCF-7 and MCF-7:2A cells were seeded in estrogen-free RPMI media containing 10% SFS at a density of 2 × 104 cells per well in 24-well plates. After 24 h, cells were treated with the respective drugs for 2, 5, and 7 days with retreatment on alternate days. The DNA content of the cells was determined as previously described  using a Fluorescent DNA Quantitation kit (Bio-Rad, Hercules, CA, USA). For each analysis, six replicate wells were used, and at least three independent experiments were performed.
Cell proliferation was also determined by cell counting using a hemocytometer. MCF-7 and MCF-7:2A cells were seeded at a density of 0.5 × 106 cells in 100 mm dishes and after 24 h cells were treated with 1 nM E2, 100 μM BSO, or 1 nM E2 plus 100 μM BSO for 7 days with re-treatment on alternate days. For each analysis, three replicate dishes were used, and at least three independent experiments were performed.
Detection of apoptosis by annexin V staining
The annexin V-fluorescein isothiocyanate (FITC) labeled Apoptosis Detection Kit I (BD Biosciences, San Jose, CA, USA) was used to detect and quantify apoptosis by flow cytometry, according to the manufacturer's instructions.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining for apoptosis
Apoptosis was also determined by the TUNEL assay using an in situ cell death detection kit conjugated with horse-radish peroxidase (POD) (Roche Applied Science, Indianapolis, IN, USA), according to the manufacturer's instructions. Briefly, fixed cells were washed, permeabilized, and then incubated with 50 μL of terminal deoxynucleotidyl transferase end-labeling cocktail for 60 min at 37°C in a humidified atmosphere in the dark. For signal conversion, slides were incubated with 50 μL of converter-POD (anti-fluorescein antibody conjugated with horseradish peroxidase) for 30 min at 37°C, rinsed with PBS, and then incubated with 50 μL of 3,3'-diaminobenzidine (DAB) substrate solution for 10 min at 25°C. The slides were then rinsed with phosphate-buffered saline (PBS), mounted under glass coverslips, and analyzed under a light microscope using an inverted Nikon TE300 (Nikon, Melville, NY, USA).
Total cellular GSH was measured using the Total Glutathione Colorimetric microplate assay Kit (Oxford Biomedical Research), according to the manufacturer's protocol. Cells were plated at 0.5 × 106/well of a six-well plate and allowed to recover overnight. After appropriate treatments, cells were washed in PBS and then lysed in 100 to 150 μl of buffer (100 mM NaPO4, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.5) containing 0.1% Triton X-100 and frozen at -80°C until analysis. To measure total glutathione, proteins were precipitated with sulfosalicylic acid at a final concentration of 1%. Samples were then spun for 10 min in a microcentrifuge to pellet proteins, and supernatant was diluted 1:20 in buffer before being measured. For all measurements, 50-μl triplicates of each sample were used for glutathione determination. The GSH level was obtained by comparing with the GSH standards and represented as nmol/mg of protein.
Mitochondrial transmembrane potential (ΔΨm) and cytochrome c release
Changes in the mitochondrial membrane potential (ΔΨm) were examined by monitoring the cells after staining with rhodamine 123. Briefly, estradiol plus BSO-treated MCF-7:2A cells were washed twice with PBS and incubated with 1 μg/mL rhodamine 123 at 37°C for 30 min. Cells were then washed twice with PBS, and Rh123 intensity was determined by flow cytometry. Cells with reduced fluorescence were counted as having lost some of their mitochondrial membrane potential.
For cytochrome c release assays, cells were lysed in lysis buffer (10 mmol/L N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.5), 10 mmol/L KCl, and 1 mmol/L EDTA) with protease inhibitor cocktail (Sigma), frozen and thawed three times, and centrifuged at 2,000 g for 5 min. The supernatants were centrifuged at 10,000 g for 15 min at 4°C, and the mitochondrial pellets were dissolved in sodium dodecyl sulfate (SDS) sample buffer, subjected to 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and analyzed by immunoblotting with monoclonal antibodies against cytochrome c and Cox IV.
RNA isolation and quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated using TRI reagent (Invitrogen) according to the manufacturer's protocol. RNA (2 μg) was reverse transcribed to cDNA using the SuperScript II RNase H-reverse transcriptase system (Invitrogen, Carlsbad, CA, USA). Aliquots of the cDNA were combined with the SYBR green kit and primers, and assayed in triplicate by real-time quantitative PCR using a GeneAmp® 5700 Sequence detection system (Applied Biosystems Inc, Foster City, CA, USA). Quantitation was performed using the comparative threshold cycle (Ct) method with 18S rRNA as the normalization gene, as previously described . GS and GPx2 primers were designed using Primer Express™ software following the manufacturer's guidelines. Primers were synthesized by Applied Biosystems. Quantitative PCR was performed using the following conditions: 40 cycles; denaturation at 95 C for 15 s, annealing at 63 C for 1 min, and polymerization at 72 C for 1 min. Primer sequences were: GS forward: CACCAGCT GGGGAAGCATCT; reverse: GGTGAGGGGAAGAGCGT GAA, GPx2 forward: TTG ATT AAG GCT TTC TTT GGT AGG; reverse: TTT CAA TAA ATC AGG TCC CAG G.
Small interfering RNA (siRNA) transfection
Bcl-2-specific siRNA was chemically synthesized by Dharmacon Inc (Chicago, IL, USA). A non-targeting siRNA duplex was used as negative control. For transfection, MCF-7:2A cells were seeded in complete medium without antibiotics the day before the experiment in 12-well plates at a density of 70,000 cells per well. After 24 h, cells were transfected with 100 nM of Bcl-2 siRNA or control siRNA, using DharmaFect 1 transfection reagent (Dharmacon Inc, Chicago, IL, USA), according to the manufacturer's protocol. The cells were harvested 48 h post transfection and analyzed by western blot. Transfected cells were also treated with estradiol for an additional 72 h and apoptotic cells were measured using annexin V staining.
Inhibition of MCF-7:2A cell tumorigenesis by BSO in nude mice
Female CrTac:NCr-Foxn1nu athymic mice (4 to 5 weeks old) were purchased from Taconic (Germantown, NY, USA). Animal experiments were conducted at the Fox Chase Cancer Center (Philadelphia, PA, USA). The research protocol was approved, and mice were maintained in accordance with institutional guidelines of the Fox Chase Cancer Center Animal Care and Use Committee. Mice were acclimatized to the animal facility for 1 week before they received injections of MCF-7:2A human breast cancer cells: 2 × 107 cells were resuspended in 100 μL PBS (Collaborative Biomedical Products, Bedford, MA, USA) and were bilaterally injected into the mammary fat pads of 20 ovariectomized mice. Tumors were allowed to develop for 20 days until they reached a mean cross-sectional area of 0.32 cm2, when treatment was initiated with placebo (saline), E2 (0.3 cm capsule), BSO (4 mmol/kg weight), or BSO (4 mmol/kg weight) plus E2 (0.3 cm capsule) for an additional 7 days. For the estradiol treatment, 0.3 cm silastic estradiol capsules (Baxter HealthCare, Mundeleine, IL, USA) were implanted subcutaneously in the mice. These capsules produced a mean serum estradiol level of 83.8 pg/mL , to achieve postmenopausal serum levels of estradiol. BSO was dissolved in saline and was administered intraperitoneally daily for 7 days. The cross-sectional tumor area was calculated by multiplying the length (l) by the width (w) by π and dividing the product by 4 (lwπ/4). Animals were given food and water ad libitum. Mice from each group (n = 5) were killed at the conclusion of the experiment and immunohistochemical analysis was performed.
Tissue preparation and immunohistochemistry
Tumors from mice treated with placebo, E2, BSO, or BSO plus E2 were excised and fixed in 10% formalin, embedded in paraffin wax blocks and sectioned. Subsequently, sections of the tumor blocks were stained with hematoxylin and eosin (H&E), Ki67, or PARP antibody (1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA) by the pathology core facility at Fox Chase Cancer Center.
Statistical analysis was performed using the Student t test, and a p value of < 0.05 was considered significant. Data are expressed as the mean ± standard error of the mean (SEM). The mean value was obtained from at least three independent experiments.
Estrogen deprivation increases glutathione levels in MCF-7:2A breast cancer cells
We next examined whether the expression of glutathione-related enzymes was altered in these cells. Using quantitative real-time PCR, we found a 6-fold increase in glutathione synthetase (GS) expression and a 40-fold increase in glutathione peroxidase 2 (GPx2) expressions in MCF-7:2A cells compared to parental MCF-7 cells (Figure 1b). Western blot analysis also showed a marked increase in GS protein level in MCF-7:2A cells compared to parental MCF-7 cells (Figure 1b, right panel).
BSO enhances the apoptotic effect of E2in MCF-7:2A cells
To further substantiate the apoptotic effect of BSO and estradiol in MCF-7:2A cells, annexin V-PI immunostaining was performed by flow cytometry. Figure 3b shows that in the BSO plus estradiol-treated group, approximately 55.6% of cells stained positive for annexin V whereas in the control group and estradiol-treated group, approximately 7.4% and approximately 15.6%, respectively, of cells stained positive for annexin V. For the BSO-treated group, only 8.7% of cells stained positive for annexin.
Role of the mitochondrial pathway in BSO plus estradiol-induced apoptosis in MCF-7:2A cells
Although estradiol, as an individual treatment, did not significantly induce apoptosis in MCF-7:2A cells, it did decrease Bcl-2 protein level in these cells. We therefore tested whether siRNA knockdown of Bcl-2 expression would sensitize MCF-7:2A cells to estradiol-induced apoptosis. Expression of Bcl-2 following knockdown was analyzed by western blotting. As expected, Bcl-2 protein levels were significantly reduced following transfection of MCF-7:2A cells with Bcl-2 siRNA compared to control siRNA (Figure 4b, top panel). Using annexin V staining, we found that apoptosis was increased by 20% in Bcl-2 siRNA transfected cells compared with cells transfected with the control siRNA (Figure 4b, bottom panel), thus suggesting that suppression of antiapoptotic factors such as Bcl-2 has the ability to partially sensitize hormone-independent MCF-7:2A cells to apoptosis.
We next examined mitochondrial membrane integrity using the Rh123 retention assay. Cells were treated with nothing (control), estradiol, BSO, or BSO plus estradiol for 48 h. Figure 4c shows that BSO plus estradiol treatment reduced Rh123 fluorescence in MCF-7:2A cells by approximately 50% compared to control, whereas, estradiol or BSO, as individual treatments, did not significantly alter Rh123 retention levels in these cells. BSO plus estradiol also enhanced cytochrome c release in MCF-7:2A cells. Figure 4d shows that in the control cells, cytochrome c was detected primarily in the mitochondria and was undetectable in the cytosol; however, in the presence of BSO plus estradiol (48 h), all of cytochrome c was observed in the cytosol. BSO or estradiol, as individual treatments, did not significantly alter mitochondrial release of cytochrome c. The translocation of cytochrome c from the mitochondria to the cytosol following BSO plus estradiol treatment coincided with cleavage of caspase 7 and PARP (Figure 4e), which is a molecular signature of apoptosis. Cleavage of PARP and caspase 7 was blocked by the pan-caspase inhibitor z-VAD (data not shown).
The apoptotic effect of BSO and estradiol in MCF-7:2A cells is regulated, in part, by JNK signaling
BSO inhibits the growth of MCF-7:2A cells in vivo
In the current study, we investigated whether suppression of the antioxidant glutathione by BSO has the ability to sensitize antihormone resistant MCF-7:2A breast cancer cells to estradiol-induced apoptosis. Our results showed that glutathione levels and the enzymes involved in its synthesis, glutathione synthetase and glutathione peroxidase, were significantly elevated in MCF-7:2A cells compared to parental MCF-7 cells and that suppression of glutathione by BSO sensitized these cells to estrogen-induced apoptosis in vitro and in vivo. The BSO-mediated estradiol-induced apoptosis was associated with a marked decrease in the expression of antiapoptotic Bcl-2 and Bcl-xL proteins and a significant increase in proapoptotic Bax protein. It is worth noting that high-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen, however, due to undesirable side effects, the use of high-dose estrogen was largely abandoned . Here, we show that the killing effect of estradiol in antihormone resistant cells can be achieved at physiological concentrations when it is combined with non-toxic concentrations of BSO. Our present findings are consistent with previous studies which have shown that the cytotoxicity of a number of chemotherapeutic drugs, including melphalan , doxorubicin , and bleomycin , are significantly enhanced when glutathione is depleted by BSO.
An important target of BSO plus estradiol-induced apoptosis appears to be Bcl-2, whose protein expression was dramatically decreased in MCF-7:2A cells following glutathione depletion. Previous studies have shown that Bcl-2 functions as an antioxidant to block apoptosis and that Bcl-2 protein levels and glutathione intracellular concentration is coordinately regulated with a decrease in either favoring cell death [23, 33]. It is believed that one mechanism by which Bcl-2 may function as an antioxidant is through upregulation of glutathione, leading to rapid detoxification of reactive oxygen species and inhibition of free radical-mediated mitochondrial damage. Bcl-2 also has the ability to shift the entire cellular redox potential to a more reduced state, which is independent of its effect on glutathione levels . It is worth noting that glutathione levels and Bcl-2 protein expression were significantly elevated in MCF-7:2A cells compared to parental MCF-7 cells. In phase I trials [34, 35], the concentration of BSO in blood has been shown to reach 0.5 to 1 mM, whereas, in mice [36, 37] the concentration has been estimated to be 5 to 6 mM following an in vivo treatment of 4 mmol/kg. In our study, we showed that 100 μM BSO decreased glutathione concentrations by approximately 60% after 24 h and that BSO enhanced the apoptotic effect of estradiol in MCF-7:2A breast cancer cells as early as 48 h after treatment. Interestingly, treatment with BSO alone did not cause apoptosis in MCF-7:2A cells, indicating that glutathione depletion alone may not trigger apoptosis in these cells. This finding is consistent with previous studies by Mirkovic et al.  which showed that inhibition of glutathione by BSO did not increase susceptibility of mouse lymphoma cells to radiation-induced apoptosis even under conditions where glutathione levels were lowered by 50%. Other groups have made similar observations using BSO . One possible explanation for this apparent contradiction might be the fact that BSO does not lower glutathione levels in mitochondria as effectively as it does in the cytoplasm . Mitochondrial glutathione concentrations are regulated and have been implicated in apoptotic cell death , hence, it would be of interest to evaluate relative glutathione concentrations in the mitochondrial matrix of MCF-7:2A cells following treatment with BSO either alone or in combination with estradiol. Another possibility could be that cellular thiols other than glutathione may play important roles in regulating apoptosis . The flavoprotein thioredoxin has been shown to be upregulated in several human tumors and is implicated in both cancer cell growth and apoptotic resistance . However, it is not known whether Bcl-2 or other apoptotic regulators can influence the levels of thioredoxin or whether such modulation may contribute to resistance in human tumor cells.
Apart from Bcl-2, we also found that proapoptotic Bax protein was markedly increased in MCF-7:2A cells by the combination of BSO plus estradiol and this induction coincided with a loss of mitochondrial membrane integrity and cytochrome c release. Bax is normally found as a monomer in the cytosol of non-apoptotic cells and it oligomerizes and translocates to the outer mitochondrial membrane in response to apoptotic stimuli and induces mitochondrial membrane permeabilization and cytochrome c release . In MCF-7:2A cells, Bax protein was induced as early as 24 h after BSO plus estradiol treatment (Figure 4) and suppression of Bax expression using siRNA was able to partially reverse the apoptotic effect of the combination treatment (data not shown). The induction of Bax coincided with cytochrome c release from the mitochondria into the cytosol, which was followed by activation of caspase 7, and PARP cleavage. It is worth noting that pretreatment of cells with the universal caspase inhibitor z-VAD almost completely blocked the apoptotic effect of BSO plus estradiol. It is also worth noting that antiapoptotic Bcl-2 and Bcl-xL proteins were also markedly decreased in MCF-7:2A cells following the combination treatment of BSO plus estradiol (Figure 4) and overexpression of Bcl-xL partially blocked the apoptotic effect of BSO plus estradiol (data not shown). This finding is important because there is evidence that suggests that the ratio rather than the amount of antiapoptotic vs proapoptotic proteins determines whether apoptosis will proceed . Thus, it is reasonable to suggest that the apoptotic effect of BSO plus estradiol is mediated, in part, by the mitochondrial pathway through their ability to alter the ratio between proapoptotic and antiapoptotic proteins in target cells.
In addition to the mitochondrial pathway, BSO plus estradiol appears to induce apoptosis, in part, through activation of the JNK signaling pathway. JNKs are a group of mitogen-activated protein kinases (MAPKs) that bind the N-terminal activation domain of the transcription factor c-Jun and phosphorylate c-Jun on amino acid residues Ser63 and Ser73 . JNKs are stimulated by multiple factors including cytokines, DNA-damaging agents, and environmental stresses and are important in controlling programmed cell death or apoptosis. The inhibition of JNKs has been shown to enhance chemotherapy-induced inhibition of tumor cell growth, suggesting that JNKs may provide a molecular target for the treatment of cancer . We found that JNK activation (as measured by the increased levels of phospho-JNK1/2 and the JNK substrate phospho-c-Jun) correlated well with BSO plus estradiol-induced apoptosis in MCF-7:2A cells and pharmacologic disruption of this pathway using the JNK inhibitor SP600125 significantly attenuated this effect. Previously, Chen and coworkers  reported that BSO enhanced the apoptotic effect of arsenic (As2O3) in leukemia and lymphoma cells through activation of JNK and upregulation of death receptor (DR)5 and that inhibition of JNK by SP600125 decreased DR5 upregulation and apoptotic induction in U937 leukemia cells treated with arsenic plus BSO. While the exact mechanism by which JNK promotes apoptosis is not currently known, the phosphorylation of transcription factors such as c-Jun and p53, as well as pro- and antiapoptotic Bcl-2 family members  has been suggested to be of importance. It is worth noting that treatment with BSO plus estradiol markedly increased phosphorylated c-Jun in MCF-7:2A cells and decreased phosphorylated Bcl-2 in these cells. These findings thus suggest that BSO plus estradiol might mediate their apoptotic effect, in part, through activation of JNK.
We have demonstrated that glutathione depletion by BSO sensitizes hormone-resistant MCF-7:2A human breast cancer cells to estradiol-induced apoptosis in vitro and in vivo. This finding has important clinical implications; particularly for the use of estrogen deprivation as long-term therapy, and it suggest that, if and when resistance develops, a strategy of treatment with estrogen combined with BSO may be effective in sensitizing resistant cells to apoptosis. It is worth noting that recently, Lonning and coworkers  reported a 33% complete response (that is, stable disease) with high dose diethylstilbestrol (DES) in postmenopausal patients with advanced breast cancer who were heavily pretreated with endocrine agents. However, 67% of the patients showed partial or no response  so the key to future clinical progress in the treatment of antihormone resistant breast cancer is to improve current treatment strategies. We are currently evaluating the optimal dose of daily estradiol therapy to reverse antihormonal resistance  but the goal is to enhance the estradiol-induced apoptotic response. The present findings suggest that BSO is indeed capable of enhancing the apoptotic effect of estradiol in antihormone resistant breast cancer cells. It is worth noting that a phase I study of BSO administered with the anticancer drug melphalan showed that continuous-infusion of BSO was relatively nontoxic and resulted in depletion of tumor glutathione [35, 47]. Thus it is possible that future clinical studies of BSO infusions combined with low dose estrogen hold the promise of improving disease control for patients with antihormone resistant ER-positive metastatic breast cancer.
fetal bovine serum
hematoxylin and eosin
c-Jun N-terminal kinase
dextran coated charcoal-treated FBS
terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling.
This work was supported by the Department of Defense Breast Program under award number BC050277 Center of Excellence (VCJ); Fox Chase Cancer Center Core Grant NIH P30 CA006927 (VCJ); Weg Fund of Fox Chase Cancer Center (VCJ); a gift from Genuardi's (VCJ), the American Cancer Society Grant IRG-92-027-14 (JSLW); the Hollenbach Family Fund (JSLW), and the NIH Career Development Grant K01CA120051-01A2 (JSLW). Histology and immunohistochemistry were performed by the Histopathology Core Facility at Fox Chase Cancer Center.
- Herold CI, Blackwell KL: Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. Clin Breast Cancer. 2008, 8: 50-64. 10.3816/CBC.2008.n.003.View ArticlePubMedGoogle Scholar
- Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H: Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol. 2008, 630: 19-34.View ArticlePubMedPubMed CentralGoogle Scholar
- Jordan VC, O'Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007, 25: 5815-5824. 10.1200/JCO.2007.11.3886.View ArticlePubMedGoogle Scholar
- Jordan VC: The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer – survival or death?. J Clin Oncol. 2008, 26: 3073-3082. 10.1200/JCO.2008.17.5190.View ArticlePubMedGoogle Scholar
- Santen RJ, Allred DC: The estrogen paradox. Nat Clin Pract Endocrinol Metab. 2007, 3: 496-497. 10.1038/ncpendmet0535.View ArticlePubMedGoogle Scholar
- Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001, 93: 1714-1723. 10.1093/jnci/93.22.1714.View ArticlePubMedGoogle Scholar
- Pink JJ, Jiang SY, Fritsch M, Jordan VC: An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res. 1995, 55: 2583-2590.PubMedGoogle Scholar
- Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005, 97: 1746-1759.View ArticlePubMedGoogle Scholar
- Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A: High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001, 67: 111-116. 10.1023/A:1010619225209.View ArticlePubMedGoogle Scholar
- Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP: Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res. 1999, 246: 183-192. 10.1006/excr.1998.4303.View ArticlePubMedGoogle Scholar
- Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, Ozols RF: Glutathione and drug resistance. Cancer Invest. 1996, 14: 158-168. 10.3109/07357909609018891.View ArticlePubMedGoogle Scholar
- Anderson ME: Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact. 1998, 111–112: 1-14. 10.1016/S0009-2797(97)00146-4.View ArticlePubMedGoogle Scholar
- Townsend DM, Tew KD, Tapiero H: The importance of glutathione in human disease. Biomed Pharmacother. 2003, 57: 145-155. 10.1016/S0753-3322(03)00043-X.View ArticlePubMedGoogle Scholar
- Hammond CL, Lee TK, Ballatori N: Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J Hepatol. 2001, 34: 946-954. 10.1016/S0168-8278(01)00037-X.View ArticlePubMedGoogle Scholar
- Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer. 2000, 89: 1440-1447. 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0.View ArticlePubMedGoogle Scholar
- Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ: Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res. 2003, 63: 312-318.PubMedGoogle Scholar
- Fulda S, Debatin KM: Targeting inhibitor of apoptosis proteins (IAPs) for diagnosis and treatment of human diseases. Recent Patents Anticancer Drug Discov. 2006, 1: 81-89. 10.2174/157489206775246539.View ArticleGoogle Scholar
- Fulda S, Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006, 25: 4798-4811. 10.1038/sj.onc.1209608.View ArticlePubMedGoogle Scholar
- Youle RJ, Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008, 9: 47-59. 10.1038/nrm2308.View ArticlePubMedGoogle Scholar
- Peter ME, Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10: 26-35. 10.1038/sj.cdd.4401186.View ArticlePubMedGoogle Scholar
- Newmeyer DD, Ferguson-Miller S: Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003, 112: 481-490. 10.1016/S0092-8674(03)00116-8.View ArticlePubMedGoogle Scholar
- Meredith MJ, Cusick CL, Soltaninassab S, Sekhar KS, Lu S, Freeman ML: Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Biochem Biophys Res Commun. 1998, 248: 458-463. 10.1006/bbrc.1998.8998.View ArticlePubMedGoogle Scholar
- Voehringer DW: BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med. 1999, 27: 945-950. 10.1016/S0891-5849(99)00174-4.View ArticlePubMedGoogle Scholar
- Swaby RF, Jordan VC: Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer. 2008, 8: 124-133. 10.3816/CBC.2008.n.012.View ArticlePubMedGoogle Scholar
- Labarca C, Paigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980, 102: 344-352. 10.1016/0003-2697(80)90165-7.View ArticlePubMedGoogle Scholar
- O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst. 1998, 90: 1552-1558. 10.1093/jnci/90.20.1552.View ArticlePubMedGoogle Scholar
- Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T, Bredesen DE: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science. 1993, 262: 1274-1277. 10.1126/science.8235659.View ArticlePubMedGoogle Scholar
- Bossy-Wetzel E, Bakiri L, Yaniv M: Induction of apoptosis by the transcription factor c-Jun. EMBO J. 1997, 16: 1695-1709. 10.1093/emboj/16.7.1695.View ArticlePubMedPubMed CentralGoogle Scholar
- Haddow AW, Paterson E: Influence of synthetic oestrogens upon advanced malignant disease. BMJ. 1944, 2: 393-398.View ArticlePubMedPubMed CentralGoogle Scholar
- Kramer RA, Greene K, Ahmad S, Vistica DT: Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res. 1987, 47: 1593-1597.PubMedGoogle Scholar
- Dusre L, Mimnaugh EG, Myers CE, Sinha BK: Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res. 1989, 49: 511-515.PubMedGoogle Scholar
- Russo A, DeGraff W, Friedman N, Mitchell JB: Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res. 1986, 46: 2845-2848.PubMedGoogle Scholar
- Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C, Bredesen DE: Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. J Neurochem. 1996, 67: 1259-1267.View ArticlePubMedGoogle Scholar
- O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF: Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 1996, 14: 249-256.PubMedGoogle Scholar
- Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G: Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997, 89: 1789-1796. 10.1093/jnci/89.23.1789.View ArticlePubMedGoogle Scholar
- Kang YJ, Uthus EO: Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats. Biochem Pharmacol. 1996, 51: 567-570. 10.1016/0006-2952(95)02221-X.View ArticlePubMedGoogle Scholar
- Morrison JP, Coleman MC, Aunan ES, Walsh SA, Spitz DR, Kregel KC: Aging reduces responsiveness to BSO- and heat stress-induced perturbations of glutathione and antioxidant enzymes. Am J Physiol Regul Integr Comp Physiol. 2005, 289: R1035-1041.View ArticlePubMedGoogle Scholar
- Mirkovic N, Voehringer DW, Story MD, McConkey DJ, McDonnell TJ, Meyn RE: Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene. 1997, 15: 1461-1470. 10.1038/sj.onc.1201310.View ArticlePubMedGoogle Scholar
- Sato N, Iwata S, Nakamura K, Hori T, Mori K, Yodoi J: Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis. J Immunol. 1995, 154: 3194-3203.PubMedGoogle Scholar
- Griffith OW, Meister A: Origin and turnover of mitochondrial glutathione. Proc Natl Acad Sci USA. 1985, 82: 4668-4672. 10.1073/pnas.82.14.4668.View ArticlePubMedPubMed CentralGoogle Scholar
- Martensson J, Meister A: Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. Proc Natl Acad Sci USA. 1989, 86: 471-475. 10.1073/pnas.86.2.471.View ArticlePubMedPubMed CentralGoogle Scholar
- Baker A, Payne CM, Briehl MM, Powis G: Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 1997, 57: 5162-5167.PubMedGoogle Scholar
- Jacobson MD, Raff MC: Programmed cell death and Bcl-2 protection in very low oxygen. Nature. 1995, 374: 814-816. 10.1038/374814a0.View ArticlePubMedGoogle Scholar
- Vasilevskaya I, O'Dwyer PJ: Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat. 2003, 6: 147-156. 10.1016/S1368-7646(03)00043-8.View ArticlePubMedGoogle Scholar
- Chen D, Chan R, Waxman S, Jing Y: Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res. 2006, 66: 11416-11423. 10.1158/0008-5472.CAN-06-0409.View ArticlePubMedGoogle Scholar
- Park J, Kim I, Oh YJ, Lee K, Han PL, Choi EJ: Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2. J Biol Chem. 1997, 272: 16725-16728. 10.1074/jbc.272.27.16725.View ArticlePubMedGoogle Scholar
- Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol. 1994, 12: 194-205.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.